Table 3.
HR | 95%CI | P | |
---|---|---|---|
Age ≥65 | 1.47 | 0.60–3.60 | 0.39 |
ECOG-PS (1 vs 0) | 0.98 | 0.41–2.35 | 0.98 |
Sex (male vs female) | 0.92 | 0.381–2.21 | 0.85 |
No. of metastatic sites ≥3 | 3.49 | 1.91–5.48 | 0.01* |
Carbohydrate antigen 19–9 ≥600 U/mL | 1.44 | 0.57–3.61 | 0.43 |
Previous radiation therapy | 0.37 | 0.04–2.94 | 0.34 |
Previous surgery | 0.94 | 0.21–4.20 | 0.94 |
Previous biliary stent | 1.51 | 0.41–5.50 | 0.53 |
Pain present | 0.84 | 0.34–2.05 | 0.70 |
FOLFIRI vs FOLFOX | 0.35 | 0.14–0.87 | 0.02* |
PFS >3 months with previous NabGem | 0.73 | 0.29–1.85 | 0.51 |
>4 cycles of Gem-NabP | 0.61 | 0.22–1.73 | 0.36 |
Note: *Statistically significant